Therapeutic Options for Treatment-Resistant Depression

  title={Therapeutic Options for Treatment-Resistant Depression},
  author={Richard C. Shelton and Olawale O. Osuntokun and Alexandra N. Heinloth and Sara A. Corya},
  journal={CNS Drugs},
Treatment-resistant depression (TRD) presents major challenges for both patients and clinicians. There is no universally accepted definition of TRD, but results from the US National Institute of Mental Health’s (NIMH) STAR*D (Sequenced Treatment Alternatives to Relieve Depression) programme indicate that after the failure of two treatment trials, the chances of remission decrease significantly.Several pharmacological and nonpharmacological treatments for TRD may be considered when optimized… 
Therapeutic Modalities for Treatment Resistant Depression: Focus on Vagal Nerve Stimulation and Ketamine
  • Aparna P. Shah, F. Carreño, A. Frazer
  • Psychology, Biology
    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2014
Both VNS and ketamine, while effective, need further research that can reveal specific targets for intervention by novel drugs and address concerns related to side-effects, especially those seen with ketamine.
The hidden third: improving outcome in treatment-resistant depression
Evaluation of the clinical evidence in TRD is complicated by the absence of a validated definition, and there is a need to move away from traditional definitions of remission based on severity of symptoms to one that includes normalisation of functioning.
What alternatives to first-line therapy for depression are effective?
  • J. S. Manning
  • Medicine, Psychology
    The Journal of clinical psychiatry
  • 2010
Clinicians need to cultivate strong therapeutic alliances with patients, use objective measurements, practice evidence-based medicine, and educate patients about the disease and its treatments to combat treatment resistance.
Treatment-resistant depression: therapeutic trends, challenges, and future directions
  • K. S. Al-Harbi
  • Psychology, Medicine
    Patient preference and adherence
  • 2012
Treatment-resistant depression continues to challenge mental health care providers, and further relevant research involving newer drugs is warranted to improve the quality of life of patients with the disorder.
Evidence for the Benefits of Nonantipsychotic Pharmacological Augmentation in the Treatment of Depression
The efficacy of augmentation with modafinil, buspirone, methylphenidate, folic acid, pindolol and lamotrigine is limited or equivocal, and more trials are needed to help develop evidence-based options for augmentation in TRD.
Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression.
There is scant evidence from open case series or randomized trials to guide practitioners in treating patients with treatment-resistant depression, but results of clinical studies are consistent with the notion that the dopamine system plays a critical role in treatment- resistant depression.
Treatment-Resistant Depression in Primary Care Across Canada
Investigating the prevalence of treatment-resistant depression in primary care centres found that patients with TRD had longer episode duration, were more likely to receive polypharmacy, and reported more AD related side effects.
Management of treatment-resistant depression.
Treatment Resistant Depression: Strategies for Primary Care
This paper reviews commonly used options for treatment after an inadequate initial antidepressant response and suggests that it is reasonable to take one or more additional steps to attempt to achieve remission.
Demographic Profile and Management Strategies of Treatment Resistant Schizophrenia and Treatment Resistant Depression in a Tertiary Care Referral Hospital
Evaluating the demographic profile and management of treatment resistant schizophrenia and treatment resistant depression in psychiatric department of a tertiary care super-specialty hospital concluded that in TRS, this specific population unresponsive to previous treatment, a combination of clozapine with aripiprazole, as well as other augmentation strategies for clozAPine, are seen worthy of further exploration.


Quetiapine plus SSRI in treatment-resistant depression: possible mechanisms
Preliminary and open data indicate that quetiapine may similarly augment SSRIs in TRD, which requires a randomized controlled trial data for confirmation of such effectiveness.
Treatment algorithms in treatment-resistant depression.
VNS Therapy in Treatment-Resistant Depression: Clinical Evidence and Putative Neurobiological Mechanisms
Evidence from neuroimaging and other studies suggests that VNS therapy acts via innervation of the nucleus tractus solitarius, with secondary projections to limbic and cortical structures that are involved in mood regulation, including brainstem regions that contain serotonergic and noradrenergic regions that project to the forebrain.
Medication Options in the Treatment of Treatment-Resistant Depression
When monotherapy provided at the maximum manufacturer-recommended doses for 3–4 weeks has failed to provide remission in depression, the diagnosis should be confirmed, psychotherapy added and psychosocial factors should receive attention.
Issues in treatment-resistant depression.
  • M. Keller
  • Psychology
    The Journal of clinical psychiatry
  • 2005
Major depressive disorder is a debilitating disease that imposes significant social and economic burdens not only on patients but also on society. Although various treatment options are available,
Diagnosis and definition of treatment-resistant depression
  • M. Fava
  • Psychology, Medicine
    Biological Psychiatry
  • 2003
Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series.
It is suggested that there may be a role for adjunctive quetiapine in treatment-resistant adolescent depression and clinical safety and efficacy trials of quet iapine appear to be warranted.
Therapeutic Alternatives for Difficult-to-Treat Depression: A Narrative Review of the State of the Evidence
  • M. Thase
  • Medicine, Psychology
    CNS Spectrums
  • 2004
There is a need for greater collaboration among academicians and organizations, such as the American Psychiatric Association, the National Institute of Mental Health, and the pharmaceutical industry, to ensure that sufficient research is conducted so that clinician's choices for patients with TRD can be guided by empirical evidence.
Treatment-resistant depression: definition and treatment approaches.
The authors address the problems of defining and treating the estimated 750,000 patients with treatment-resistant depression by suggesting treatment strategies for resistant depression should use systematic algorithms to avoid confusion and limit "therapeutic nihilism" in the patient and physician.